DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. The company is headquartered in San Diego, California and currently employs 206 full-time employees. The company went IPO on 2017-06-20. The firm is engaged in developing and marketing non-invasive genomics tests to aid in the diagnosis and management of melanoma. Its technology enhances evaluation of lesions suspicious for melanoma using non-invasive sample collection and detecting genomic markers associated with melanoma to identify higher risk lesions or rule out melanoma with a 99% or higher negative predictive value (NPV). The company offers DermTech Melanoma Test (the DMT), which is a non-invasive way to enhance evaluation of pigmented lesions suspicious for melanoma. Its genomics platform has been designed to work with its Smart Sticker, which provides an easy and non-invasive way to collect a skin sample, in contrast to the existing standard of care of using a scalpel to biopsy suspicious lesions. The company also provides its research services and technology platform on a contract basis to pharmaceutical companies that use the technology to support their clinical trials.